HARMS / Cummins / Agency for Healthcare Research / /
Continent
North America / Europe / /
Country
Senegal / Benin / /
Event
FDA Phase / /
Facility
Blood Institute / Sickle Cell Center / Mayo Clinic / Medical College of Georgia / /
IndustryTerm
Care of Sickle Cell Disease / Treatment for Patients With Sickle Cell Disease / treatment of sickle cell disease / Treatment for Sickle Cell Disease / /
MedicalCondition
sepsis/infection / hypersplenism / marrow depression / HIV / FOR SICKLE CELL DISEASE / liver failure / sickle cell anemia / acute chest syndrome / lymphadenopathy / chronic hepatic disease / renal disease / infections / hepatic disease / hepatic insufficiency / HYDROXYUREA FOR SICKLE CELL DISEASE / disease / titration dose HYDROXYUREA FOR SICKLE CELL DISEASE / stroke / pulmonary hypertension / fever / pain / Thrombocytopenia Neutropenia / NR Other toxicities HYDROXYUREA FOR SICKLE CELL DISEASE / NA NA NA NA HYDROXYUREA FOR SICKLE CELL DISEASE / hepatic failure / Sickle Cell Disease / Quality deficiency / aseptic necrosis / infection / deficiency / Pediatr Blood Cancer / renal failure / rash / /
MedicalTreatment
birth control / contraception / cognitive behavioral therapy / /
Organization
National Heart / Lung / and Blood Institute / Data Coordinating Center / Johns Hopkins University Evidence-based Practice Center / Knowledge and Encounter Research Unit / Medical College of Georgia / NR PL / Agency for Healthcare Research and Quality / /
Person
D. Anas Shahrour Larry Prokop / M. Hassan Murad / P.H. Ahmad Hazem / B.A. Rebecca Mullan / Median / Victor M. Montori / Al-Jam / Black Hispanic / /
Hydroxyurea for Sickle Cell Disease: A Systematic Review of Benefits, Harms, and Barriers of Utilization, 2012